MDL-100240
| Code | Size | Price |
|---|
| TAR-T28005-5mg | 5mg | £1,251.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28005-50mg | 50mg | £2,464.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28005-100mg | 100mg | £3,283.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
MDL-100240 is a dual inhibitor of angiotensin-converting enzyme (ACE) and neprilysin with a balanced activity. MDL 100240 shows an impressive effectiveness both in preventing and in regressing hypertension-induced vascular remodeling and cardiac hypertrophy.
CAS:
142695-08-7
Formula:
C26H28N2O5S
Molecular Weight:
480.58
Purity:
0.98
SMILES:
[H][C@]12CCC[C@H](N1C(=O)[C@H](Cc1ccccc21)NC(=O)[C@H](Cc1ccccc1)SC(C)=O)C(O)=O
References
1. Seccia TM, Belloni AS, Guidolin D, Sticchi D, Nussdorfer GG, Pessina AC, Rossi GP. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. J Hypertens. 2006 Jul;24(7):1419-27. PubMed PMID: 16794493.
2. Cirillo I, Martin NE, Brennan B, Barrett JS. The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240. J Clin Pharmacol. 2004 Dec;44(12):1379-84. PubMed PMID: 15545308.
3. Emmons GT, Argenti R, Martin LL, Martin NE, Jensen BK. Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers. J Clin Pharmacol. 2004 Aug;44(8):901-5. PubMed PMID: 15286094.
4. Pfister M, Martin NE, Haskell LP, Barrett JS. Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240. J Clin Pharmacol. 2004 Jun;44(6):621-31. PubMed PMID: 15145970.